Non-Small Cell Lung Cancer (ASCO) Basic Listing

Updates in Non-Small Cell Lung Cancer

From the ASCO Annual Meeting

Conference Coverage

Concurrent Osimertinib Improved PFS Among Patients With Unresectable, Stage 3 EGFR-Mutated Non-Small Cell Lung Cancer

06/02/2024

Suresh Ramalingam, MD

Suresh Ramalingam, MD, discussed results from the phase 3 LAURA study which demonstrated that administration of osimertinib following definitive chemoradiation improved PFS among patients with unresectable, stage 3, EGFR-mutated NSCLC.

Suresh Ramalingam, MD, discussed...

06/02/2024

Oncology

Paul Paik, MD, Memorial Sloan Kettering Cancer Center

Videos

Tepotinib Demonstrates Durable Clinical Activity Among Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer

07/17/2023

Paul K. Paik , MD;

At the 2023 ASCO Annual Meeting, Paul Paik shared the long-term outcomes of tepotinib for patients with MET exon 14 skipping non-small cell lung cancer.

At the 2023 ASCO Annual Meeting,...

07/17/2023

Oncology

Ticiana Leal, MD, Winship Cancer Institute

Videos

Tumor Treating Fields Plus Standard of Care Improved Overall Survival Among Patients With Metastatic Non-Small Cell Lung Cancer

07/17/2023

Ticiana Leal , MD;

At the 2023 ASCO Annual Meeting, Ticiana Leal, MD, discussed the results of the phase 3 LUNAR study, which found that the addition of tumor treating fields to standard of care improved overall survival among patients with metastatic non-small...

At the 2023 ASCO Annual Meeting,...

07/17/2023

Oncology

Videos

Adjuvant Osimertinib Improved Overall Survival for Patients With EGFR-Mutant NSCLC

06/19/2023

At the 2023 ASCO Annual Meeting, Roy Herbst, MD, PhD, shared results from the overall survival analysis of the phase 3 ADAURA trial, evaluating adjuvant osimertinib for patients with resected EGFR-mutated non-small cell lung cancer.

At the 2023 ASCO Annual Meeting,...

06/19/2023

Oncology

Sunvozertinib Demonstrates Superior Antitumor Efficacy Over Current Available Therapy for NSCLC With EGFR Exon20 Insertion Mutations

06/19/2023

Stephanie Holland ;

Results from the phase 2 WU-KONG6 study demonstrate superior antitumor efficacy with sunvozertinib in pretreated patients with NSCLC and EGFR exon20 insertion mutations when compared to current available therapies.

Results from the phase 2...

06/19/2023

Oncology

Conference Coverage

Datopotamab Deruxtecan Demonstrates Safety, Activity Among Patients With Non-Small Cell Lung Cancer

06/09/2023

Stephanie Holland ;

Findings from the phase 1b TROPION-Lung02 study presented at the 2023 ASCO Annual Meeting, demonstrate tolerable safety and notable first-line activity with datopotamab deruxtecan plus pembrolizumab among patients with NSCLC.

Findings from the phase 1b...

06/09/2023

Oncology

Conference Coverage

BLU-495 Demonstrates Safety and Activity in Advanced EGFR-Mutant NSCLC

06/09/2023

Amber Denham ;

According to phase 1/2 data presented at the 2023 ASCO Annual Meeting, BLU-945, as a monotherapy and in combination with osimertinib, was generally well tolerated and showed strong on-target EGFR ctDNA reduction.

According to phase 1/2 data...

06/09/2023

Oncology

Videos

PALOMA Study Identifies Recommended Phase 2 Dose of Subcutaneous Amivantamab for Advanced Solid Malignancies

06/04/2023

Anna Minchom, MBBCh, MRCP, MD(Res), discusses updated safety results from the PALOMA trial and the identified recommended phase 2 dose for subcutaneous biweekly administration of amivantamab for patients with advanced solid malignancies.

Anna Minchom, MBBCh, MRCP,...

06/04/2023

Oncology

Recent News

News

Tumor Mutational Status May Predict Recurrence, Survival Patterns for Patients With Early-Stage Non-Small Cell Lung Cancer

11/18/2024

Stephanie Holland ;

According to results from a retrospective analysis, tumor mutational status can potentially predict recurrence and survival patterns for patients with surgically resected, stage I non-small cell lung cancer.

According to results from a...

11/18/2024

Oncology

News

FDA Grants Approval to Revumenib for Patients With R/R Acute Leukemia With KMT2A Translocation

11/17/2024

On November 15, 2024, the FDA approved menin inhibitor revumenib for adult and pediatric patients 1 year and older with relapsed/refractory acute leukemia with KMT2A translocation.

On November 15, 2024, the FDA...

11/17/2024

Oncology

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology